dm+d

19405002

Articles

Search Articles

New Medicines

External infections of the eye and its adnexa caused by netilmicin sensitive bacteria.

Information

New formulation
SIFI
Not Known

Development and Regulatory status

Licensed but not launched
Launched
None
Jun 20Communication from New Line Pharma: netilmicin products are to be transferred to new MAA, SIFI, who are planning to launch by end of 2021 [6].
Dec 19Approved in UK for the topical treatment of external infections of the eye and its adnexa caused by netilmicin sensitive bacteria. Available in a single-dose container [1,2].

Category

Netilmicin is an aminoglycoside antibiotic that binds to the bacterial 30S ribosomal subunit and interferes with mRNA binding and the acceptor tRNA site, thus inhibiting protein synthesis in bacteria [3]
Acute infective conjunctivitis accounts for approximately 1% of all GP consultations in the UK. Bacterial conjunctivitis is the second most common cause of infectious conjunctivitis. Between 50–75% of cases of infective conjunctivitis in children are thought to be due to bacterial infection [4].
External infections of the eye and its adnexa caused by netilmicin sensitive bacteria.
Topical

Evidence based evaluations